Clinical Trial for Parkinson's Disease Gets a Green Light in the US.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 33545076.
- Also identified by DOI 10.1016/j.stem.2021.01.013.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Cell-based therapy is expected as an alternative treatment for Parkinson's disease. In this issue of Cell Stem Cell, two accompanying papers (Kim et al., 2021; Piao et al., 2021) report the induction of clinically applicable dopaminergic neurons from human embryonic stem cells and the results of pre-clinical study toward a clinical trial.
Medical subject headings
- Human Embryonic Stem Cells
- Parkinson Disease